Haisco Pharmaceutical Group (002653.SZ): Innovation drug HSK46575 tablet IND application accepted

Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Group Pharmaceuticals Co., Ltd., received an "Acceptance Notice" from the National Medical Products Administration on September 23, 2024. The drug is named HSK46575. HSK46575 is an orally administered, potent, and highly selective small molecule inhibitor developed independently by the company, intended for the treatment of prostate cancer.